Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration

Hepatology

Volumn 52, Issue 3, 2010, Pages 1046-1059

  Teixeira Clerc, Fatima ^a,b   Belot, Marie Pierre ^a,b   Manin, Sylvie ^a,b   Deveaux, Vanessa ^a,b   Cadoudal, Thomas ^a,b   Chobert, Marie Noele ^a,b   Louvet, Alexandre ^a,b   Zimmer, Andreas ^c   Tordjmann, Thierry ^d   Mallat, Ariane ^a,b   Lotersztajn, Sophie ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c UNIVERSITY OF BONN   (Germany)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CANNABINOID 2 RECEPTOR; CARBON TETRACHLORIDE; CYCLINE; GELATINASE A; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MESSENGER RNA; MOLSIDOMINE; TUMOR NECROSIS FACTOR ALPHA; 1,1-DIMETHYLBUTYL-1-DEOXY-DELTA(9)-THC; CANNABINOID;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL FRACTIONATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LIVER CELL; LIVER INJURY; LIVER PROTECTION; LIVER REGENERATION; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PARACRINE SIGNALING; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGONISTS; ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; LIVER RESECTION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TOXIC HEPATITIS;

ALANINE TRANSAMINASE; ANIMALS; APOPTOSIS; ASPARTATE AMINOTRANSFERASES; CANNABINOIDS; CARBON TETRACHLORIDE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; HEPATECTOMY; HEPATOCYTES; INTERLEUKIN-6; LIVER REGENERATION; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PARACRINE COMMUNICATION; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTOR, CANNABINOID, CB2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956644099     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23779     Document Type: Article

References (42)

1. Mallat A, Lotersztajn S. Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol 2008;294:G9-G12.
2. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462. (Pubitemid 44394908)
3. Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S, Tean van Nhieu J, et al. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. Plos One 2009;4:e5844.
4. Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, Manin S, et al. CB2 receptors as new therapeutic targets during liver diseases. Br J Pharmacol 2008;153:286-289.
5. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nat Med 2005;434:782-786.
6. Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, Mukhopadhyay P, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 2007;21:1788-1800.
7. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 2006;103:696-701.
8. Defer N, Wan J, Souktani R, Escoubet B, Perier M, Caramelle P, et al. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J 2009;23:2120-2130.
9. Mallat A, Teixeira-Clerc F, Deveaux V, Lotersztajn S. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin Ther Targets 2007;11:403-409. (Pubitemid 46290962)
10. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, et al. CB1 cannabinoid receptor antagonism: a novel strategy for the treatment of liver fibrosis. Nat Med 2006;12:671-676.
11. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al. Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. HEPATOLOGY 2005;42:63-71.
12. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, Mukhopadhyay P, et al. Paracrine activation of hepatic CB(1) receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008;7:227-235.
13. Osei-Hyiaman D, Depetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298-1305.
14. Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, et al. Daily cannabis use, a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008;134:432-439.
15. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001;7:827-832.
16. Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martin P, Fernandez-Varo G, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002;122:85-93.
17. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005;128:742-755. (Pubitemid 40585376)
18. Munoz-Luque J, Ros J, Fernandez-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008;324:475-483.
19. Hegde VL, Hegde S, Cravatt BF, Hofseth LJ, Nagarkatti M, Nagarkatti PS. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol Pharmacol 2008;74:20-33.
20. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 2000;396:141-149. (Pubitemid 30265571)
21. Serriere-Lanneau V, Teixeira-Clerc F, Li L, Schippers M, de Wries W, Julien B, et al. The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing. FASEB J 2007;21:2005-2013.
22. Nicou A, Serriere V, Hilly M, Prigent S, Combettes L, Guillon G, et al. Remodelling of calcium signalling during liver regeneration in the rat. J Hepatol 2007;46:247-256.
23. Li L, Grenard P, Tran-Van-Nhieu JT, Julien B, Mallat A, Habib A, et al. Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology 2003;125:460-469. (Pubitemid 36929428)
24. Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 2004;5:836-847.
25. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. HEPATOLOGY 2006;43:S45-S53.
26. Morio LA, Chiu H, Sprowles KA, Zhou P, Heck DE, Gordon MK, et al. Distinct roles of tumor necrosis factor-alpha and nitric oxide in acute liver injury induced by carbon tetrachloride in mice. Toxicol Appl Pharmacol 2001;172:44-51.
27. Aram G, Potter JJ, Liu X, Torbenson MS, Mezey E. Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration. HEPATOLOGY 2008;47:2051-2058.
28. Rai RM, Lee FY, Rosen A, Yang SQ, Lin HZ, Koteish A, et al. Impaired liver regeneration in inducible nitric oxide synthase-deficient mice. Proc Natl Acad Sci U S A 1998;95:13829-13834.
29. Kim YM, Talanian RV, Billiar TR. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem 1997;272:31138-31148.
30. Michalopoulos GK. Liver regeneration. J Cell Physiol 2007;213:286-300.
31. 4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J Hepatol 2005;42:548-556.
32. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005;45:605-628. (Pubitemid 40261819)
33. Siegmund SV, Qian T, de Minicis S, Harvey-White J, Kunos G, Vinod KY, et al. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J 2007;21:2798-2806.
34. Avraham Y, Zolotarev O, Grigoriadis NC, Poutahidis T, Magen I, Vorobiav L, et al. Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice. Am J Gastroenterol 2008;103:3047-3056.
35. Kovalovich K, DeAngelis RA, Li W, Furth EE, Ciliberto G, Taub R. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. HEPATOLOGY 2000;31:149-159. (Pubitemid 30033701)
36. Gao B. Therapeutic potential of interleukin-6 in preventing obesity-and alcohol-associated fatty liver transplant failure. Alcohol 2004;34:59-65.
37. Luedde T, Trautwein C. Intracellular survival pathways in the liver. Liver Int 2006;26:1163-1174.
38. Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. HEPATOLOGY 2006;43:474-484.
39. Passino MA, Adams RA, Sikorski SL, Akassoglou K. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. Science 2007;315:1853-1856.
40. Kalinichenko VV, Bhattacharyya D, Zhou Y, Gusarova GA, Kim W, Shin B, et al. Foxf1 +/- mice exhibit defective stellate cell activation and abnormal liver regeneration following CCl4 injury. HEPATOLOGY 2003;37:107-117.
41. Sanz S, Pucilowska JB, Liu S, Rodriguez-Ortigosa CM, Lund PK, Brenner DA, et al. Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. Gut 2005;54:134-141.
42. Trim N, Morgan S, Evans M, Issa R, Fine D, Afford S, et al. Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. Am J Pathol 2000;156:1235-1243. (Pubitemid 30660002)